$11.71
0.69% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US36322Q1076
Symbol
GLTO
Sector
Industry

Galecto Inc Stock price

$11.71
-2.21 15.86% 1M
-7.79 39.95% 6M
-6.29 34.94% YTD
-5.74 32.89% 1Y
-82.79 87.61% 3Y
-363.29 96.88% 5Y
-363.29 96.88% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.08 0.69%
ISIN
US36322Q1076
Symbol
GLTO
Sector
Industry

Key metrics

Market capitalization $14.52m
Enterprise Value $-8.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.28
P/B ratio (TTM) P/B ratio 0.53
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-22.16m
Free Cash Flow (TTM) Free Cash Flow $-29.96m
Cash position $22.86m
EPS (TTM) EPS $-23.45
P/E forward negative
Short interest 1.63%
Show more

Is Galecto Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Galecto Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Galecto Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Galecto Inc:

Buy
100%

Financial data from Galecto Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.77 0.77
54% 54%
-
-0.77 -0.77
54% 54%
-
- Selling and Administrative Expenses 11 11
1% 1%
-
- Research and Development Expense 9.62 9.62
76% 76%
-
-21 -21
58% 58%
-
- Depreciation and Amortization 0.77 0.77
54% 54%
-
EBIT (Operating Income) EBIT -22 -22
57% 57%
-
Net Profit -25 -25
51% 51%
-

In millions USD.

Don't miss a Thing! We will send you all news about Galecto Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Galecto Inc Stock News

Neutral
GlobeNewsWire
about one month ago
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that it will implement a 1-for-25 Reverse Stock Split of its common stock (the “Reverse Stock Split”), effective at 5:00 p.m. Eastern Time on Thursday, August 29, 2024. The Reverse Stock Split, whic...
Neutral
GlobeNewsWire
5 months ago
An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study exploring the combination of pembrolizumab (Keytruda®) and Galecto's GB1211, an oral galectin-3 inhibitor, in patients with metastatic melanoma and head and neck squamous cell carcinoma An NCI-supported Phase 2 investigator-initiated trial at th...
Neutral
GlobeNewsWire
9 months ago
Six of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ≥ 1-grade reduction in collagen fibrosis of the bone marrow, validating LOXL2 as a clinical fibrosis target Six of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ≥ 1-grade reduction in collagen fibrosis of the bone marrow, ...
More Galecto Inc News

Company Profile

Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. Its product portfolio includes GB0139, GB1211, GB2064, and GB1211. The company was founded by Ulf Nilsson, Hakon Leffler, Tariq Sethi, and Hans T. Schambye in 2011 and is headquartered in Copenhagen, Denmark.

Head office United States
CEO Hans Schambye
Employees 13
Founded 2011
Website www.galecto.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today